by Truveta staff | Sep 16, 2025 | Research
Continuous glucose monitoring (CGM) is increasingly recognized not only for its role in diabetes management but also for its potential impact on broader health outcomes. A recent consensus statement highlighted the need for additional evidence on CGM use in people...
by Truveta staff | Aug 4, 2025 | Data
Why do patients stop taking a medication? Was it due to side effects, access barriers, or lack of efficacy? These are not just clinical questions; they’re strategic ones. Understanding treatment discontinuation is essential for improving therapy design, informing...
by Truveta staff | Nov 7, 2024 | Data
GLP-1 medications are revolutionizing the way we treat type 2 diabetes and obesity. First discovered forty years ago, GLP-1 receptor agonists were initially approved for type 2 diabetes in 2005, with the first weight-loss-specific approval following in 2014. Flash...
